Dr. Ahmad Doroudian reports

BETTERLIFE FILES PATENT FOR TD-0148A FOR TREATMENT OF CLUSTER HEADACHES AND RELATED DISORDERS

Betterlife Pharma Inc. has applied for patent protection of new compositions of 2-bromo-LSD for its use in the treatment of cluster headaches, neuropathic pain and a range of mental health conditions, including depression, anxiety and posttraumatic stress disorder, and related disorders.

Betterlife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application. TD-0148A is a second-generation lysergic acid diethylamide (LSD) derivative molecule that does not cause hallucinations, and therefore is not subject to controlled substance regulations. In addition, the synthesis of TD-1048A is via non-controlled substance synthetic routes and therefore is not subject to controlled substance regulatory restrictions.

Betterlife is already in advanced stages of GMP (good manufacturing practice) manufacturing TD-0148A and initiated the necessary preclinical IND-enabling (investigational new drug) studies for TD-0148A. TD-0148A is currently in preclinical pharmacology and other IND-enabling studies and in 2022, Betterlife will file its IND and start phases 1 and 2 in healthy subjects for major depressive disorder.

Ahmad Doroudian, chief executive officer of Betterlife, commented: "The inventions covered by this provisional patent filing hold great promise, and help us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a $6.85-billion (U.S.) industry by 2027. We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and a range of mental health conditions, including depression, anxiety and PTSD, and related disorders."

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing two compounds, TD-0148A and TD-010, to treat neuro-psychiatric and neurological disorders.

TD-0148A, which is in preclinical and IND-enabling studies, is the only non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for TD-0148A eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, migraines, posttraumatic stress disorder and other neuro-psychiatric and neurological disorders. The global depression drugs market reached $12.41-billion (U.S.) in 2019 and projected to reach near $25-billion (U.S.) by 2030. According to the World Health Organization, depression is one of the leading causes of disability, impacting approximately 265 million people in the world.

TD-010, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. Betterlife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency and insomnia. The global benzodiazepines market is expected to grow to $4.15-billion (U.S.) in 2017 (from $3.48-billion (U.S.) in 2019) at a compound annual growth rate of 2.25 per cent.

Betterlife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.